172939-18-3

Upstream product

• 58990-26-4 methyl 4-deoxy-β-L-erythro-pentopyranoside 
• 100-39-0 benzyl bromide 
• 176198-99-5 methyl 4-O-[(4-methylphenyl)sulfonyl]-α-D-lyxopyranoside 

Downstream Products

• 188892-82-2 C₂₆H₃₉F₃O₄Si₂ 
• 172939-24-1 6-O-acetyl-3,4-di-O-benzyl-1,5-dideoxy-1,1,1-trifluoro-L-arabino-hexitol 
• 173008-87-2 Acetic acid (3S,4R,5S)-3,4-bis-benzyloxy-6,6,6-trifluoro-5-hydroxy-hexyl ester 
• 172939-25-2 3,4-di-O-benzyl-1,5-dideoxy-1,1,1-trifluoro-L-arabino-hexitol 
• 1054656-97-1 Acetic acid (3S,4S,5S)-3,4-bis-benzyloxy-6,6,6-trifluoro-5-trifluoromethanesulfonyloxy-hexyl ester 
• 172939-22-9 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-L-erythro-pentose trimethylene dithioacetal 
• 172939-21-8 2,3-di-O-benzyl-4-deoxy-L-erythro-pentose trimethylene dithioacetal 
• 172939-23-0 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-aldehydo-L-erythro-pentose 

Relevant academic research and scientific papers

Fluorine-containing anthracycline derivatives having hydroxyl groups(s) mono- or di-o-aminoalkanoylated in the sugar moiety thereof

To provide novel fluorine-containing anthracycline derivatives having high antitumor activities and a solubility in water, there have now been synthesized a 7-O-(2,6-dideoxy-2-fluoro-3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-α-L-talopyranosyl)daunomycinone or -adriamycinone of general formula (I) shown below, as well as a 7-O-(3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-2,6-dideoxy-2,6,6,6-tetrafluoro-α-L-talopyranosyl- or -2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone of general formula (II) shown below: General formula (I) STR1 General formula (II) STR2 wherein either one or both of A1 and A2 is or are an α-amino acid residue or an ω-amino acid residue and T denotes a fluorine or hydrogen atom. The novel fluorine-containing anthracycline derivatives of general formulae (I) and (II) are highly active against tumors and soluble in water, and they are useful as antitumor agents administrable in the form of injectable solution.

A 5′-(trifluoromethyl)anthracycline glycoside: Synthesis of antitumor-active 7-O-(2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone

7-O-(2,6-Dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone (3), whose substituent at C-5′ is a lipophilic trifluoromethyl group, has been prepared by coupling of 3,4-di-O-acetyl-2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl bromide (20) wi